ES2605454T3 - Métodos para reducir la neurodegeneración - Google Patents

Métodos para reducir la neurodegeneración Download PDF

Info

Publication number
ES2605454T3
ES2605454T3 ES12796892.3T ES12796892T ES2605454T3 ES 2605454 T3 ES2605454 T3 ES 2605454T3 ES 12796892 T ES12796892 T ES 12796892T ES 2605454 T3 ES2605454 T3 ES 2605454T3
Authority
ES
Spain
Prior art keywords
methods
neurodegeneration
reduce neurodegeneration
melatonin
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12796892.3T
Other languages
English (en)
Inventor
Rondo Paul Middleton
Brian Michael Zanghi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA filed Critical Nestec SA
Application granted granted Critical
Publication of ES2605454T3 publication Critical patent/ES2605454T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/184—Hormones
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/132—Heterocyclic compounds containing only one nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/168—Steroids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Feed For Specific Animals (AREA)

Abstract

La cantidad de melatonina que reduce la neurodegeneración para el uso en reducir la neurodegeneración en un animal canino, dicha melatonina se administra en cantidades comprendidas aprox. entre 1 ng/kg/día y 2 mg/kg/día.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
ES12796892.3T 2011-06-08 2012-06-04 Métodos para reducir la neurodegeneración Active ES2605454T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161520332P 2011-06-08 2011-06-08
US201161520332P 2011-06-08
PCT/US2012/040658 WO2012170322A1 (en) 2011-06-08 2012-06-04 Methods for reducing neurodegeneration

Publications (1)

Publication Number Publication Date
ES2605454T3 true ES2605454T3 (es) 2017-03-14

Family

ID=47296378

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12796892.3T Active ES2605454T3 (es) 2011-06-08 2012-06-04 Métodos para reducir la neurodegeneración

Country Status (12)

Country Link
US (1) US20140113949A1 (es)
EP (1) EP2717695B1 (es)
JP (1) JP6284473B2 (es)
CN (1) CN103582421A (es)
AU (1) AU2012268562B2 (es)
BR (1) BR112013031460A2 (es)
CA (1) CA2838461C (es)
ES (1) ES2605454T3 (es)
MX (1) MX360787B (es)
RU (1) RU2013158254A (es)
WO (1) WO2012170322A1 (es)
ZA (1) ZA201400115B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114557315B (zh) * 2022-02-11 2022-12-20 中国农业大学 一种降低动物胃产甲烷量的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1331313A (zh) * 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人p70核糖体S6激酶11.77和编码这种多肽的多核苷酸
WO2003077900A1 (en) * 2002-03-14 2003-09-25 Prevention, L.L.C. A unifying mechanism and methods to prevent cancer and neurodegenerative diseases
EP1546369A4 (en) * 2002-08-12 2007-01-17 Univ Michigan DIAGNOSIS AND TREATMENT OF DISEASES THROUGH DEFECTS IN THE TUBEROUS SKLEROSEPFAD
US7361681B2 (en) * 2003-03-28 2008-04-22 Sygnis Bioscience Gmbh & Co. Kg Method of treating amytrophic lateral sclerosis using melatonin
JP4993900B2 (ja) * 2005-11-28 2012-08-08 国立大学法人 東京医科歯科大学 記憶障害抑制剤
WO2009120378A2 (en) * 2008-03-27 2009-10-01 Nestec S.A. Methods for increasing absorption of peptides, peptidomimetics, and other gastrointestinal transport protein substrates

Also Published As

Publication number Publication date
EP2717695A1 (en) 2014-04-16
EP2717695A4 (en) 2014-06-18
WO2012170322A1 (en) 2012-12-13
MX360787B (es) 2018-11-16
EP2717695B1 (en) 2016-11-02
CA2838461C (en) 2019-12-03
AU2012268562A1 (en) 2013-12-19
US20140113949A1 (en) 2014-04-24
BR112013031460A2 (pt) 2016-08-16
ZA201400115B (en) 2015-11-25
JP6284473B2 (ja) 2018-02-28
JP2014518899A (ja) 2014-08-07
CN103582421A (zh) 2014-02-12
CA2838461A1 (en) 2012-12-13
AU2012268562B2 (en) 2016-06-16
MX2013014430A (es) 2014-01-20
RU2013158254A (ru) 2015-07-20

Similar Documents

Publication Publication Date Title
ES2496092T3 (es) El uso de amisulprida para tratar náuseas y vómitos posoperatorios
ES2524551T3 (es) Composición de gel
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
ES2620754T3 (es) Uso de 5-androstano (alquil)-3,5,6-triol en la preparación de fármacos neuroprotectores
CL2015002802A1 (es) Composiciones y métodos para producir cetosis elevada y sostenida
CL2012002318A1 (es) Compuestos derivados de tieno [2,3-d]pirimidina, inhibidores de quinasa mnk1 y mnk2; composición farmaceutica; que los comprende; y su uso en el tratamiento de enfermedades metabolicas, hematopoyeticas, neurodegenerativas, renales, inflamatorias y cancer.
UY33317A (es) Nuevos derivados de pirazol
AR077629A1 (es) Mimetico de smac
ECSP10010684A (es) Agonistas mezclados, basados en gip para el tratamiento de trastornos metabólicos y obesidad.
CL2013001558A1 (es) El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico.
NI201600093A (es) Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina
MX373291B (es) Composiciones y metodos para el uso de ésteres de forbol
MX2013007622A (es) Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson.
AR087093A1 (es) Composicion que mejora la palatabilidad que comprende aminoacidos libre para usar en alimentos para mascotas
MX348933B (es) Composiciones, formas de dosificacion y coadministracion de un compuesto agonista opioide y un compuesto analgesico.
ES2543850A2 (es) Uso de complejos metálicos miméticos de SOD como agentes alimentarios y como cosméticos
EA201491609A1 (ru) Модуляторы x рецепторов печени
ES2527583T3 (es) Confitería aireada de tipo malvavisco y procedimiento de preparación
MX2013005643A (es) Iminas alfa, beta-insaturadas.
ES2508165T3 (es) Lactoferrina y sustancia blanca
GT201300304A (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
ES2660019T3 (es) Parche que contiene diclofenaco y tiocolchicósido
CO6670561A2 (es) Destilado de ácido láurico para alimento animal
ES2494140T3 (es) Suspensión de compuesto de boro
ES2619428T3 (es) Composición en polvo para desinfección de las ubres de los animales lecheros